ImCare Biotech, LLC services

Overexpression of a novel apoptosis inhibitor, serine protease inhibitor Kazal (SPIK), has been demonstrated in HCC and other cancer patients. In addition, high levels of SPIK are closely associated with early recurrence in cancer patients following surgical resection. Because recurrence of cancer often implies the immune system’s inability to clear lingering oncogenic cells, early cancer recurrence in patients with high levels of SPIK suggests that the overexpression of SPIK may interfere with the elimination of these oncogenic cells by the immune system.